Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Ovarian Neoplasms
  • Phenylthiohydantoin

abstract

  • We present the first evidence that the second-generation anti-androgen enzalutamide may possess efficacy in the treatment of ovarian cancer, paving the way for the future clinical trials.

publication date

  • November 8, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5546102

Digital Object Identifier (DOI)

  • 10.1080/07357907.2016.1242598

PubMed ID

  • 27824515

Additional Document Info

start page

  • 1

end page

  • 4